• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 11:14:27 AM ET
    $LH
    Medical Specialities
    Health Care
    Get the next $LH alert in real time by email
    SC 13G/A 1 tv01244-laboratorycorpofamer.htm SCHEDULE 13G/A laboratorycorpofamericaholdings

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  Laboratory Corp. of America Holdings

    Title of Class of Securities:  Common Stock

    CUSIP Number:  50540R409

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  50540R409

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    162,958

    7.  SOLE DISPOSITIVE POWER

    9,976,036

    8.  SHARED DISPOSITIVE POWER

    429,566

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    10,405,602

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.68%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Laboratory Corp. of America Holdings

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    358 South Main Street
    Burlington, North Carolina 27215

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    50540R409

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    10,405,602

      (b) Percent of Class:

    10.68%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  162,958

    (iii)  sole power to dispose of or to direct the disposition of:  9,976,036

    (iv)  shared power to dispose or to direct the disposition of:  429,566

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $LH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LH

    DatePrice TargetRatingAnalyst
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    4/2/2025$276.00Buy
    Redburn Atlantic
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    10/30/2024Hold → Buy
    HSBC Securities
    10/1/2024$235.00Neutral
    Piper Sandler
    3/25/2024$250.00Hold → Buy
    Argus
    More analyst ratings

    $LH
    SEC Filings

    View All

    Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    5/27/26 8:04:15 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    5/26/26 4:01:56 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SD filed by Labcorp Holdings Inc.

    SD - LABCORP HOLDINGS INC. (0000920148) (Filer)

    5/22/26 4:26:23 PM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer

    Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family membersResearch will also assess the clinical impact of broader genetic testing in colorectal cancer careBURLINGTON, N.C., May 29, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC). The trial will evaluate approaches to increase germline genetic testing among at-risk family members, as well as the

    5/29/26 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects

    New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatmentBURLINGTON, N.C., May 28, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy. Labcorp now offers genotype testing for all DPYD Tier 1 and Tier 2 variants recommended by the Association for Molecular Pathology (AMP).

    5/28/26 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp to Present at the Jefferies Global Healthcare Conference

    BURLINGTON, N.C., May 27, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, from 12:15 pm to 12:45 pm ET. The presentation can be accessed via a live webcast on the Labcorp Investor Relations website at ir.labcorp.com. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days following the event.About LabcorpLa

    5/27/26 8:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Schechter Adam H sold $1,502,314 worth of shares (5,903 units at $254.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 107,234 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    5/13/26 9:30:44 AM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form 4 filed by Schechter Adam H

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    3/30/26 12:58:09 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form 4 filed by Graham Anita Z

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    3/30/26 12:57:06 PM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Labcorp Holdings Inc. downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00

    7/10/25 9:03:30 AM ET
    $LH
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

    Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

    4/2/25 8:50:29 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. upgraded by Citigroup with a new price target

    Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

    3/4/25 7:36:42 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Leadership Updates

    Live Leadership Updates

    View All

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Labcorp Appoints John H. Sampson, M.D., Ph.D., to Board of Directors

    BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H. Sampson, M.D., Ph.D., MHSc, MBA, to its Board of Directors, effective February 9, 2026. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical r

    2/9/26 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Appoints Victor Bulto to Board of Directors

    Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025. Bulto is an accomplished global executive with 25 years of experience in healthcare, and a proven track record of leadin

    11/24/25 8:30:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Financials

    Live finance-specific insights

    View All

    Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance

    Results from Operations for first quarter 2026 versus first quarter 2025:Revenue: $3.54 billion vs. $3.35 billion, up 5.8%Diluted EPS: $3.35 vs. $2.52, up 32.8%Adjusted EPS: $4.25 vs. $3.84, up 10.6%Raised Full-Year Enterprise Revenue and Adjusted EPS guidance:Revenue guidance of 5.0% to 6.1%; up 20 basis points at the midpointAdjusted EPS range of $17.70 to $18.35; up 13 cents at the midpointAdvanced leadership in specialty and companion diagnostics and expanded strategic health systems collaborationsCollaborated with Optum.ai to enhance patient and provider experienceBURLINGTON, N.C., April 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc (NYSE:LH), a global leader of innovative and comprehen

    4/30/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Declares Quarterly Dividend

    BURLINGTON, N.C., April 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 11, 2026, to stockholders of record as of the close of business on May 29, 2026. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident

    4/9/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Announces 2025 Fourth Quarter and Full Year Results

    Company Provides 2026 GuidanceFinancial results from Operations versus 2024:Revenue: Q4 of $3.52 billion vs $3.33 billion; Full year of $13.95 billion vs $13.01 billionDiluted EPS: Q4 of $1.98 vs $1.70; Full year of $10.46 vs $8.84Adjusted EPS: Q4 of $4.07 vs $3.45; Full year of $16.44 vs $14.57Free Cash Flow: Q4 of $490.3 million vs. $665.1 million; Full year of $1.21 billion vs $1.10 billionProvided Full-Year 2026 Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue of $14.61 billion to $14.79 billion; midpoint growth of 5.4%Adjusted EPS of $17.55 to $18.25; midpoint growth of 8.9%Free Cash Flow of $1.24 billion to $1.36 billion; midpoint growth of 7.8%Expanded partnerships

    2/17/26 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Laboratory Corporation of America Holdings (Amendment)

    SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

    2/13/24 5:08:06 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Laboratory Corporation of America Holdings (Amendment)

    SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)

    7/24/23 4:20:26 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

    2/10/21 11:14:27 AM ET
    $LH
    Medical Specialities
    Health Care